The tumours of 17 patients (32%) harboured a genomic mutation in one of the MMR genes, suggesting that the dMMR status of tumours of the remaining patients was due to epigenetic alterations as (e.g. MLH1 promoter methylation). This evidence concerns the gene MRC1 and neoplasm.